osteoprotegerin


Also found in: Medical, Acronyms, Wikipedia.

osteoprotegerin

[¦äs·tē·prō′teg·ərin]
(biochemistry)
A protein that plays a central role in regulating bone mass.
Mentioned in ?
References in periodicals archive ?
Bartold, "Effect of smoking on concentrations of receptor activator of nuclear factor [kappa] B ligand and osteoprotegerin in human gingival crevicular fluid," Journal of Clinical Periodontology, vol.
First, it causes osteoblasts to secrete osteoprotegerin rather than RANKL, causing reduced activation of osteoclasts.
Osteoprotegerin (OPG), receptor activator of nuclear factor-[kappa]B (RANK), and RANK ligand (RANKL), are proteins that regulate osteoclast formation and differentiation (Lacey et al.
Association of PPARy allelic variation, osteoprotegerin and abdominal aortic aneurysm," Clinical Endocrinology, vol.
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.
In addition to the Framingham risk factors, vascular calcification in persons receiving renal replacement therapy is also associated with inflammation, disturbances in bone mineralization, hyperphosphatemia, osteoprotegerin, matrix Gla protein, and a deficiency in fetuin-A or alpha-Heremans-Schmid glycoprotein and deficiency in Vitamin K (Wang, 2009).
17,19) First, cytokines bind to mesenchymal stem cells and increase the expression of receptor-activator NF-[kappa][beta] ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) and decrease osteoprotegerin production, which effectively increases activation of osteoclasts (cells responsible for resorption of bone tissue).
RANKL also binds to osteoprotegerin (OPG), a decoy receptor, which reduces resorption.
Serum parathyroid hormone (PTH), osteocalcin (OC), osteoprotegerin (OPG), receptor activator for nuclear factor Kappa B ligand (RANk-L) and bone-related degradation products of C-terminal peptides of type I collagen (CTX-I) were measured by enzyme linked immunosorbent assays specific for rat (Rat Bone Panel 3--PTH and Osteocalcin; Rat Bone Panel 1--osteoprotegerin; Rat Bone Panel 2--RANK-L of the Millipore--Billerica, MA, USA; CTX-I of the Immunodiagnostic Systems --Scottsdale, AZ, USA).
Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
The commercial release of the Mouse Sclerostin ELISA serves to expand ALPCO's current bone metabolism portfolio which consists of assays including Human Sclerostin, Human Osteoprotegerin and sRANKL, Mouse/Rat Osteoprotegerin and sRANKL as well as kits specific for Human and Rodent Osteocalcin.
High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.